Annual Report and Accounts

The report describes BerGenBio's 2020 clinical progress in oncology and its response to COVID-19, including two ongoing bemcentinib studies. It presents sustainability as foundational to the business and identifies contributions to SDGs 3, 8, 9 and 17. The report also highlights a growing year-end workforce of 49 employees, with initiatives supporting diversity, wellbeing and professional development. Financially, Group revenue was NOK 0.6 million, while the company continued investing heavily in research and development.